Semaglutide vs Tirzepatide in 2026

Semaglutide and tirzepatide are both peptides, and both are studied for weight and metabolic health, but they are not the same molecule. Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, GLP-1 and GIP. Both are once-weekly injections that start low and step up slowly.

This page walks through the studied differences in plain terms so you can choose with confidence and have a smarter conversation with your physician. At pru, both are prescribed by a licensed doctor, filled by a licensed pharmacy, and sold to you at cost.

Semaglutide vs tirzepatide: the quick answer

The core difference between semaglutide and tirzepatide is how many receptors each one activates. Semaglutide is a single-agonist peptide that targets the GLP-1 receptor. Tirzepatide is a dual-agonist peptide that targets both the GLP-1 receptor and the GIP receptor.

In head-to-head studies of the branded drugs, tirzepatide's dual action produced more weight loss on average, so pru typically points people toward tirzepatide when the priority is results, and toward semaglutide when the priority is cost, since semaglutide is the more affordable of the two. Whichever way you lean, a licensed physician has the final say on whether it is right for you.

Both peptides live in weight loss and metabolism. Below, we compare them the way a clinician would: mechanism, dosing, titration, side effects, and fit.

How semaglutide and tirzepatide work in the body

Semaglutide works by mimicking one gut hormone, and tirzepatide mimics two. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It signals fullness, slows how fast your stomach empties, and helps regulate blood sugar. Semaglutide is a peptide built to act like GLP-1, so it engages that single pathway.

Tirzepatide adds a second signal. Along with GLP-1, it activates GIP (glucose-dependent insulinotropic polypeptide), another gut hormone involved in insulin response and how the body handles fat and sugar. Because tirzepatide is one molecule that engages two receptors, researchers call it a dual agonist. That dual action is the main studied difference between the two peptides.

• Semaglutide: single GLP-1 receptor agonist. The same peptide family behind the branded drugs Ozempic and Wegovy, which are separate FDA-approved products made by Novo Nordisk.
• Tirzepatide: dual GLP-1 and GIP receptor agonist. The same peptide family behind Mounjaro and Zepbound, which are separate FDA-approved products made by Eli Lilly.
• Both are peptides, which is exactly the category pru focuses on.

That receptor difference shapes the dosing ladder and the side-effect pattern below.

Dosing and titration for semaglutide and tirzepatide

Both peptides start at a low dose and step up slowly, but they climb on different ladders. This gradual increase is called titration, and it gives your body time to adjust so side effects stay manageable. Semaglutide is dosed in milligrams that step up roughly every four weeks toward a target maintenance dose.

Tirzepatide uses its own separate ladder, also stepping up in stages about every four weeks. The tables below show common schedules studied in the branded products. Your prescriber sets your actual doses and may hold you at any step.

Semaglutide also exists in an oral form in the branded market, while tirzepatide is injection-only. For the compounded, prescribed peptides pru offers, both are given as a once-weekly injection. See the full compounded semaglutide and compounded tirzepatide guides for detail.

How the side-effect profiles compare

Both peptides share the same general side-effect profile, and both are studied most for gastrointestinal effects. The most commonly reported effects for GLP-1 medicines are nausea, diarrhea, constipation, and vomiting. These tend to show up most in the first one to four weeks after a dose increase, then ease as your body adapts. That pattern is a big reason both peptides are titrated slowly.

In the large clinical trial programs behind these molecules, gastrointestinal effects were the most common events for both, and most were mild to moderate and temporary. Rates differ by dose and by trial, so the two peptides have broadly similar, manageable side-effect profiles rather than one being clearly gentler for everyone. Some people who do not tolerate one peptide do better on the other, which is one reason having a prescriber matters.

• Most common: nausea, diarrhea, constipation, vomiting, often strongest right after a dose step-up.
• Usually temporary: effects commonly ease within days to a couple of weeks as the body adjusts.
• Titrate slowly: the whole point of the low-and-slow schedule is to keep effects tolerable.
• Report serious symptoms: severe or lasting abdominal pain, signs of a gallbladder problem, or an allergic reaction should go to your prescriber right away.

Who semaglutide or tirzepatide may suit

On average, tirzepatide tends to produce more weight loss than semaglutide, but there is no universal winner. The right fit depends on your health history, other conditions, how you tolerate the medicine, your response over time, and your goals. Some people start on one peptide and switch to the other based on how they respond. That flexibility is a feature of working with a licensed physician instead of guessing. Here is the comparison to reason over.

If you are still deciding, the best peptides for weight loss guide puts both in context. The choice is yours to make with your prescriber.

Brand names and who makes them

Semaglutide and tirzepatide each show up under two brand names, made by two different drugmakers. Semaglutide is the active molecule in Ozempic and Wegovy, both made by Novo Nordisk. Tirzepatide is the active molecule in Mounjaro and Zepbound, both made by Eli Lilly. These are separate, FDA-approved products, and each brand has its own approved use. Knowing which name maps to which molecule makes the rest of this comparison easier to follow.

These brand names are listed here only so you can tell the two molecules apart. The peptide pru offers is not made by Novo Nordisk or Eli Lilly.

What the head-to-head studies show

When researchers compared the two molecules head to head, tirzepatide showed a larger average weight change than semaglutide. In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, adults on Eli Lilly's tirzepatide (Zepbound) lost about 20.2% of body weight over 72 weeks, compared with about 13.7% for those on Novo Nordisk's semaglutide (Wegovy).

These are the results for the branded, FDA-approved drugs as studied. Compounded semaglutide and compounded tirzepatide are distinct compounded medicines that have not been studied the same way, so these numbers describe the branded products, not a promise about any compounded peptide.

A separate 2024 cohort study in JAMA Internal Medicine, comparing people taking Novo Nordisk's branded semaglutide against Eli Lilly's branded tirzepatide in real-world practice, pointed in the same direction, with tirzepatide associated with larger average weight change. A larger trial average is not a prediction for any one person, which is why your prescriber weighs your own health history, tolerance, and goals before confirming the molecule you chose is right for you.

Switching, stopping, and how to decide

Yes, people do switch between semaglutide and tirzepatide, and it is a decision made with a prescriber rather than on your own. Common reasons to switch are how well one is tolerated, how a person responds over time, and supply. Because pru works with a licensed physician, a switch is part of your care: your prescriber reviews how you have done, and adjusts the plan if it makes sense for you.

It also helps to know what happens when you stop. For both molecules, the clinical research on the branded, FDA-approved drugs shows that weight often returns after the medicine is discontinued, because the appetite signal they provide goes away. This is one reason clinicians treat these as long-term tools rather than a short course, and one reason having ongoing oversight matters.

So how do you actually decide between them? Not from a chart alone. pru's content points you toward the peptide that fits your priorities, and your prescriber weighs your health history, other conditions, tolerance, response over time, and goals before setting the plan and the dose. That is the whole value of a prescriber in the loop, and it is how pru handles both peptides.

How pru handles semaglutide and tirzepatide

At pru, both peptides follow the same clear, legitimate path. Guided by pru's content, you choose semaglutide or tirzepatide, and a licensed physician reviews your health history and confirms your choice is appropriate for you, or advises against it, and sets your dose. A state-licensed 503A compounding pharmacy prepares your medicine for you as a named patient.

It ships to your door. This individualized 503A route, where a physician prescribes and a licensed pharmacy fills for a specific patient, is the legitimate path. It is different from the mass production of drug copies that the FDA restricted after it declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in late 2024.

Here is what is important to be precise about. The peptide you get from pru is a prescribed, individualized, pharmacy-grade compounded medication. It is not FDA-approved, and it is not the branded drug. Ozempic, Wegovy, Mounjaro, and Zepbound are separate, FDA-approved products made by Novo Nordisk or Eli Lilly. pru's compounded peptide is a distinct, individualized product, and we compete on access, transparency, individualized care, and oversight.

And the medicine is priced at cost. A flat membership of about $50 a month, billed annually, funds the platform. Every peptide is then itemized: pharmacy fill, supplies, shipping, and consult, with no markup on the medicine itself. That is the whole idea behind pru. Peptides made simple, for everyone. Deciding to take your metabolic health seriously is a smart, responsible move, and pru exists to make that proactive choice the accessible one: real physicians, pharmacy-grade medicine, and pricing that stays out of the way.

When you are ready to take the next step, start with semaglutide or tirzepatide, or see exactly how pricing works.

Related reading

• Semaglutide vs Ozempic and Wegovy
• Tirzepatide vs Mounjaro and Zepbound
• Compounded semaglutide, explained
• Semaglutide dosage and titration
• see it on pru

Common questions